ATE311900T1 - Adjuvanzien zur verwendung in impfstoffen - Google Patents

Adjuvanzien zur verwendung in impfstoffen

Info

Publication number
ATE311900T1
ATE311900T1 AT99310514T AT99310514T ATE311900T1 AT E311900 T1 ATE311900 T1 AT E311900T1 AT 99310514 T AT99310514 T AT 99310514T AT 99310514 T AT99310514 T AT 99310514T AT E311900 T1 ATE311900 T1 AT E311900T1
Authority
AT
Austria
Prior art keywords
adjuvantages
vaccines
Prior art date
Application number
AT99310514T
Other languages
English (en)
Inventor
Don Dearwester
Leroy Swearingin
David Stewart Roberts
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE311900T1 publication Critical patent/ATE311900T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT99310514T 1999-01-29 1999-12-23 Adjuvanzien zur verwendung in impfstoffen ATE311900T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11770599P 1999-01-29 1999-01-29
US12176099P 1999-02-26 1999-02-26

Publications (1)

Publication Number Publication Date
ATE311900T1 true ATE311900T1 (de) 2005-12-15

Family

ID=26815550

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05023118T ATE533504T1 (de) 1999-01-29 1999-12-23 Bordetella bronchiseptica impfstoff
AT99310514T ATE311900T1 (de) 1999-01-29 1999-12-23 Adjuvanzien zur verwendung in impfstoffen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05023118T ATE533504T1 (de) 1999-01-29 1999-12-23 Bordetella bronchiseptica impfstoff

Country Status (16)

Country Link
US (6) US6572861B1 (de)
EP (2) EP1023904B1 (de)
JP (3) JP2000219636A (de)
CN (2) CN1126568C (de)
AR (2) AR035474A1 (de)
AT (2) ATE533504T1 (de)
AU (2) AU769539B2 (de)
BR (2) BRPI0017566B1 (de)
CA (2) CA2296244C (de)
CY (2) CY1105684T1 (de)
DE (1) DE69928763T2 (de)
DK (2) DK1616573T3 (de)
ES (2) ES2374628T3 (de)
NZ (2) NZ502341A (de)
PT (1) PT1616573E (de)
TW (1) TW585777B (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU769539B2 (en) * 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US6676958B2 (en) * 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
US7279163B1 (en) * 2002-03-21 2007-10-09 The United States Of America, As Represented By The Secretary Of Agriculture Water-in-oil emulsion vaccines
NZ538394A (en) * 2002-08-26 2008-06-30 Pfizer Prod Inc Vaccine for respiratory and reproductive system infections in cattles
HRP20050660A2 (en) 2003-01-29 2006-02-28 Pfizer Products Inc. Canine vaccines against bordetella bronchiseptica
PL1613346T3 (pl) * 2003-04-04 2013-03-29 Zoetis Services Llc Poddane mikrofluidyzacji emulsje typu olej w wodzie i kompozycje szczepionek
US8637047B2 (en) * 2003-10-30 2014-01-28 Boehringer Ingelheim Vetmedica, Inc. Erysipelothrix rhusiopathiae-haemophilus parasuis vaccine and methods of using the same
CN1323718C (zh) * 2004-03-15 2007-07-04 中国农业科学院兰州兽医研究所 一种利用植物油佐剂制备动物病毒性、细菌性疫苗的方法
FR2878746B1 (fr) * 2004-12-02 2007-02-23 Vetoquinol Sa Sa Nouvelle composition pharmaceutique utilisable dans le domaine des vaccins
CN1320924C (zh) * 2005-01-07 2007-06-13 邢为藩 一种自乳化疫苗佐剂及其制备方法
AU2007281934B2 (en) 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
HUE036180T2 (hu) 2006-09-26 2018-06-28 Infectious Disease Res Inst Szintetikus adjuvánst tartalmazó vakcina készítmény
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2008058035A1 (en) * 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
ES2588705T3 (es) 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
US9138470B2 (en) * 2007-11-02 2015-09-22 The Johns Hopkins University Multi-component L2 vaccine for prevention of human papilloma virus infection
CN101428145B (zh) * 2007-11-05 2013-01-02 北京生泰尔生物科技有限公司 新型疫苗佐剂
CA2723918C (en) 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
CN102076358B (zh) 2008-06-27 2016-08-17 硕腾有限责任公司 新颖的佐剂组合物
WO2010042481A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
PT3281947T (pt) 2009-04-03 2020-05-07 Univ Chicago Composições e métodos relacionados com variantes da proteína a (spa)
HUE031051T2 (en) * 2009-06-05 2017-06-28 Infectious Disease Res Inst Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
WO2011063264A1 (en) 2009-11-20 2011-05-26 University Of Chicago Methods and compositions related to immunogenic fibrils
US9849174B2 (en) 2009-11-20 2017-12-26 The Board Of Regents Of The University Of Texas System Methods and compositions related to immunogenic fibrils
WO2011100508A2 (en) 2010-02-12 2011-08-18 Arizona Board Of Regents For And On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
SG183514A1 (en) 2010-03-11 2012-10-30 Immune Design Corp Vaccines for pandemic influenza
EP2555794A4 (de) 2010-04-05 2014-01-15 Univ Chicago Zusammensetzungen und verfahren im zusammenhang mit protein-a-(spa)-antikörpern als immunreaktionsverstärker
EP2563401A1 (de) 2010-04-30 2013-03-06 Telormedix SA Verfahren zur auslösung einer immunreaktion
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
EP2563404B1 (de) 2010-04-30 2016-09-21 Urogen Pharma Ltd. Phospholipid-wirkstoffanaloga
EP2588120B1 (de) 2010-07-02 2017-11-15 The University of Chicago Zusammensetzungen und verfahren bezüglich protein-a (spa)-varianten
EP2614074A1 (de) 2010-09-09 2013-07-17 The University of Chicago Verfahren und zusammensetzungen mit schützenden staphylokokken-antigenen
WO2012042857A1 (ja) * 2010-09-28 2012-04-05 共立製薬株式会社 粘膜アジュバント組成物
EP3632463A1 (de) 2011-04-08 2020-04-08 Immune Design Corp. Immunogene zusammensetzungen und verfahren zur verwendung der zusammensetzungen zur induzierung humoraler und zellulärer immunreaktionen
US20120288515A1 (en) 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
IN2014CN02581A (de) 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
GB201205237D0 (en) 2012-03-26 2012-05-09 Univ Edinburgh Adjuvant
HRP20201127T1 (hr) 2012-04-26 2020-11-27 University Of Chicago Antigeni stafilokokne koagulaze i metode primjene istih
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
WO2014039978A2 (en) 2012-09-10 2014-03-13 Szathmary Dr Susan Vaccine to prevent mycoplasmal infection in waterfowl
EP2903987B1 (de) 2012-10-01 2017-09-20 Urogen Pharma Ltd. Phospholipid-wirkstoffanaloga
EP2986303B1 (de) 2013-04-18 2020-02-26 Immune Design Corp. Gla-monotherapie zur verwendung in der krebsbehandlung
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN115154596B (zh) * 2013-11-26 2025-06-17 硕腾服务有限责任公司 诱导免疫应答的组合物
PL3166634T3 (pl) 2014-07-11 2021-12-27 Zoetis Services Llc Nowe kompozycje szczepionek przeciwko wirusowi biegunki epidemicznej świń
CN108064165B (zh) 2015-02-27 2022-06-14 衣阿华州立大学研究基金会股份有限公司 猪流行性腹泻病毒株和由其产生的免疫原性组合物
CA3010977A1 (en) 2016-01-11 2017-07-20 Zoetis Services Llc Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
US11013798B2 (en) 2016-03-21 2021-05-25 South Dakota Board Of Regents Orf virus-based platform for vaccine delivery
US11246924B2 (en) 2016-04-01 2022-02-15 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
US10662226B2 (en) 2016-10-28 2020-05-26 The Regents of the University of Caiifomia Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
CN107027749B (zh) * 2017-05-24 2021-04-09 浙江工业大学 一种复合乳化剂及其在复配毒死蜱农药中的应用
ES2705378A1 (es) * 2017-09-22 2019-03-22 Decco Worldwide Post Harvest Holdings B V Metodo para el tratamiento y control de fisiopatias de postcosecha de frutas mediante recubrimientos comestibles.
US11413336B2 (en) 2018-03-23 2022-08-16 Board Of Regents, The University Of Texas System Coccidioides antigens and methods of their use
US20210340185A1 (en) 2018-08-29 2021-11-04 Centre Hospitalier Universitaire Vaudois Ebola vaccine compositions and methods of using same
US11208167B2 (en) 2018-11-15 2021-12-28 Kuat Innovations Llc Bicycle rack with actuated arm
BR112021022902A2 (pt) 2019-05-14 2022-01-25 Univ Chicago Métodos e composições que compreendem variantes de proteína a staphylococcus (spa)
CN114315985A (zh) 2020-09-29 2022-04-12 硕腾服务有限责任公司 减毒猪流行性腹泻病毒
CN115216451A (zh) 2021-04-16 2022-10-21 硕腾服务有限责任公司 伪狂犬病病毒疫苗
TW202327646A (zh) 2021-10-15 2023-07-16 美商輝瑞大藥廠 Rna分子
CN113907044A (zh) * 2021-11-09 2022-01-11 福建省连江县刘氏兔业养殖场 一种抗病猪品系的培育方法及其应用
AU2022410694A1 (en) 2021-12-17 2024-07-04 Pfizer Inc. Polynucleotide compositions and uses thereof
WO2023144779A1 (en) 2022-01-28 2023-08-03 Pfizer Inc. Coronavirus antigen variants
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
EP4608441A1 (de) 2022-10-27 2025-09-03 Pfizer Inc. Immunogene zusammensetzungen gegen influenza und rsv
EP4630049A1 (de) 2022-12-11 2025-10-15 Pfizer Inc. Immunogene zusammensetzungen gegen influenza und rsv
CN118267462A (zh) 2022-12-29 2024-07-02 硕腾服务有限责任公司 接种猪以抗伪狂犬病病毒的方法
WO2024154052A1 (en) 2023-01-16 2024-07-25 Pfizer Inc. Immunogenic compositions and methods of inducing an immune response against varicella zoster virus
MX2025014990A (es) 2023-06-14 2026-02-03 Pfizer Metodo para estabilizar acido ribonucleico (rna)
WO2025027492A1 (en) 2023-07-31 2025-02-06 Pfizer Inc. Coronavirus antigen variants
WO2025126019A1 (en) 2023-12-13 2025-06-19 Pfizer Inc. Rna molecules
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025186719A1 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions and uses thereof
WO2025186725A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Improved lnp formulations and uses thereof
US20260061042A1 (en) 2024-03-26 2026-03-05 Pfizer Inc. Polynucleotide compositions and uses thereof
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026030275A1 (en) 2024-08-01 2026-02-05 Pfizer Inc. Rna molecules

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4075321A (en) * 1973-05-04 1978-02-21 Agence Nationale De Valorisation De La Recherche (Anvar) Vaccines, the process for preparing the same and the applications thereof
AT350181B (de) 1977-05-04 1979-05-10 Schuller Walter Dr Verfahren zur herstellung einer mischvaccine
US4137115A (en) * 1977-11-07 1979-01-30 Patrick Lambert Joining structure
US4237115A (en) * 1977-11-23 1980-12-02 Bactex, Inc. Method of immunization against enterotoxogenic infection by Escherichia coli
US4261925A (en) 1978-04-05 1981-04-14 The Dow Chemical Company Surfactants
US4504275A (en) 1983-03-24 1985-03-12 Imperial Chemical Industries Plc Emulsifying agents
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4933179A (en) 1983-08-22 1990-06-12 Syntex (U.S.A.) Inc. Feline leukemia virus antigen vaccines
US5424323A (en) * 1985-01-18 1995-06-13 Cetylite Industries, Inc. Sterilant composition
US5338748A (en) 1985-01-18 1994-08-16 Cetylite Industries, Inc. Sterilant composition
DE3517805A1 (de) 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Impfstoff zur immunisierung von schweinen gegen rhinitis atrophicans (schnueffelkrankheit)
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US4789544A (en) * 1986-05-23 1988-12-06 Midcon Labs. Inc. Co-vaccination using non-O-carbohydrate side-chain gram-negative bacteria preparation
US5019388A (en) * 1986-10-14 1991-05-28 Norden Laboratories Inc. Bordetella bronchiseptica vaccine
US4888169A (en) * 1986-10-14 1989-12-19 Norden Laboratories, Inc. Bordetella Bronchiseptica vaccine
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
US5209929A (en) * 1987-03-19 1993-05-11 Washington State University Research Foundation Immunization against Babesiosis using purified merozoite surface antigens of Basesia bigemina
US5376369A (en) 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
US5069901A (en) * 1988-02-03 1991-12-03 Jones Elaine V Preparation of a recombinant subunit vaccine against pseudorabies infection
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
FR2649012B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
US5223253A (en) * 1989-09-28 1993-06-29 American Home Products Corporation Bovine vaccine compositions and method for preventing trichomonas infections using same
US5578308A (en) * 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
DK0515415T3 (da) * 1990-02-12 1995-11-27 Smithkline Beecham Biolog Hidtil ukendt vaccine og fremgangsmåde til fremstilling deraf
CA2082155C (en) * 1990-05-29 2008-04-15 Krishnaswamy I. Dayalu Swine pneumonia vaccine and method of preparation
AU8195391A (en) 1990-06-13 1992-01-07 Smithkline Beecham Corporation Pasteurella multocida toxoid vaccines
US5695769A (en) * 1990-06-13 1997-12-09 Pfizer Inc. Pasteurella multocida toxoid vaccines
US5242686A (en) * 1990-11-07 1993-09-07 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
JP3043809B2 (ja) 1991-11-15 2000-05-22 ファイザー・インコーポレイテッド グラム陰性菌ワクチン
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5422277A (en) * 1992-03-27 1995-06-06 Ortho Diagnostic Systems Inc. Cell fixative composition and method of staining cells without destroying the cell surface
DE4222153C2 (de) 1992-07-06 1998-12-03 Peter Siegfried Verfahren zur Entölung von Rohlecithin
EP0626452B1 (de) * 1993-05-17 1999-08-11 Akzo Nobel N.V. Impstoff gegen Streptococcus suis-Infektion
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
ES2183867T3 (es) * 1994-02-18 2003-04-01 Solidose L L C Inoculacion de animales con materiales biologicos secados en peletes.
GB2289279B (en) 1994-05-13 1998-09-16 Iberica Cyanamid Diagnostic kits and vaccines containing recombinant PRRSV proteins
CN1279978C (zh) * 1994-06-10 2006-10-18 财团法人化学及血清疗法研究所 博代氏杆菌所产皮肤坏死毒素和类毒素的纯化方法
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5625038A (en) * 1994-07-27 1997-04-29 Henderson; Louise M. Monoclonal antibodies specific for Erysipelothrix rhusiopathiae
US5603951A (en) 1994-11-09 1997-02-18 Hanmi Pharm. Ind. Co., Ltd. Cyclosporin-containing soft capsule compositions
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
EP0781559B1 (de) * 1995-11-30 2007-02-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Öladjuvierter Impfstoff und Verfahren zu seiner Herstellung
DK0835930T3 (da) 1996-10-09 2001-06-18 Akzo Nobel Nv Europæiske vaccinestammer af porcint reproduktions- og respirationssyndrom-virus. (PRRSV)
ZA982870B (en) * 1997-04-10 1998-10-09 Akzo Nobel Nv Live attenuated bacteria of the species actinobacillus pleuropneumoniae
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
AU769539B2 (en) * 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US6585981B1 (en) 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae

Also Published As

Publication number Publication date
NZ502341A (en) 2001-08-31
US20030175309A1 (en) 2003-09-18
BRPI0000126B1 (pt) 2015-07-14
US20050058667A1 (en) 2005-03-17
JP4785365B2 (ja) 2011-10-05
JP5167469B2 (ja) 2013-03-21
NZ513202A (en) 2003-02-28
HK1059739A1 (en) 2004-07-16
CN1449825A (zh) 2003-10-22
BR0000126A (pt) 2001-05-02
TW585777B (en) 2004-05-01
CN1449825B (zh) 2012-08-22
EP1616573A3 (de) 2007-05-09
EP1023904A2 (de) 2000-08-02
US6733754B2 (en) 2004-05-11
AU6537299A (en) 2000-08-03
BRPI0017566B1 (pt) 2015-11-10
JP2000219636A (ja) 2000-08-08
EP1616573B1 (de) 2011-11-16
CA2455134A1 (en) 2000-07-29
CN1126568C (zh) 2003-11-05
AR055422A2 (es) 2007-08-22
BRPI0000126B8 (pt) 2022-05-10
US6814971B2 (en) 2004-11-09
ES2251164T3 (es) 2006-04-16
DK1023904T3 (da) 2005-12-27
US20030175299A1 (en) 2003-09-18
CY1112521T1 (el) 2015-12-09
AR035474A1 (es) 2004-06-02
US7393535B2 (en) 2008-07-01
EP1023904A3 (de) 2002-08-21
ES2374628T3 (es) 2012-02-20
ATE533504T1 (de) 2011-12-15
HK1030166A1 (en) 2001-04-27
DE69928763T2 (de) 2006-06-29
US20030175298A1 (en) 2003-09-18
CN1270838A (zh) 2000-10-25
CA2455134C (en) 2010-05-11
AU769539B2 (en) 2004-01-29
AU2004201021A1 (en) 2004-04-08
US6572861B1 (en) 2003-06-03
CA2296244A1 (en) 2000-07-29
EP1616573A2 (de) 2006-01-18
CA2296244C (en) 2004-04-27
CY1105684T1 (el) 2010-12-22
US20030175308A1 (en) 2003-09-18
DE69928763D1 (de) 2006-01-12
JP2005041883A (ja) 2005-02-17
DK1616573T3 (da) 2012-01-30
EP1023904B1 (de) 2005-12-07
JP2004002479A (ja) 2004-01-08
PT1616573E (pt) 2012-01-11

Similar Documents

Publication Publication Date Title
ATE311900T1 (de) Adjuvanzien zur verwendung in impfstoffen
DE60143301D1 (de) Polyarylcarboxamide zur verwendung als lipidsenker
DE69934825D1 (de) Filter zur verwendung in der medizintechnik
DE59911409D1 (de) Heizvorrichtung zur Lufterwärmung
NO20014325L (no) Vaksine
DE60112595D1 (de) System zur gewichtsklassifizierung
PL363005A1 (pl) Szczepionki
ATA159499A (de) Einrichtung zur in vivo-messung von grössen in lebenden organismen
FR2803504B1 (fr) Oreiller anatomique
DE60015879D1 (de) Wirbelsäulenimplantat
DE60024585D1 (de) Lasergerät zur steinzertrümmerung mit absaugung
FR2815535B1 (fr) Implant pediculaire
FI19992753L (fi) Menetelmä vastaanottimessa ja vastaanotin
DE60002650D1 (de) Öladjuvierter Impfstoff
NO20020763D0 (no) Vaksine
ID30091A (id) Metode untuk menyiapkan l-fenilefrina hidroklorida
DE60022254T2 (de) Verbesserungen in Reifen
DE50012435D1 (de) Dichtungselement zur Verwendung in Fahrzeugen
DE59909904D1 (de) Umhängenadel zur Maschenübertragung
ATE299716T1 (de) Zusammensetzung zur luftverbesserung
EP1173874A4 (de) Plasmabrenner und verfahren zur verwendung
CU23064A3 (es) Conjunto implante dental-transportador
DE60022585D1 (de) Gegenstand zur Aufnahme von Körperausscheidungen
DE50113937D1 (de) System zur datenübermittlung
ATA17142000A (de) Flachheizkörper

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1023904

Country of ref document: EP